Date: 2015-12-15
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Amgen (USA - CA)
Product: Imlygic® (talimogene laherparepvec)
Action
mechanism: oncolytic virus/immunotherapy product. Talimogene laherparepvec is an investigational oncolytic immunotherapy designed to selectively replicate in tumors (but not normal tissue) and to initiate an immune response to target cancer cells that have metastasized. Talimogene laherparepvec was designed to work in two important and complementary ways. First, it is injected directly into tumors where it replicates inside the tumor's cells causing the cell to rupture and die in a process called lysis. The rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a system-wide immune response where white blood cells are able to seek out and target cancer that has spread throughout the body.
Disease: advanced non CNS tumors
Therapeutic area: Cancer - Oncology
Country:
Trial
details: This phase 1 study to evaluate the safety of intralesional talimogene laherparepvec administration in pediatric subjects with advanced non-CNS tumors that are amenable to direct injection. (NCT02756845)
Latest
news: * On December 15, 2015, a Phase I trial sponsored by Amgen was published on the NIH website ClinicalTrials.gov for Imlygic® (talimogene laherparepvec) and is currently recruiting participants.
